{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:25:25Z","timestamp":1790115925545,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cjca.2024.10.010","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T23:57:50Z","timestamp":1729123070000},"page":"167-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study"],"prefix":"10.1016","volume":"41","author":[{"given":"Paloma","family":"Remior-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"G\u00f3mez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Garc\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gallego-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laroussi","family":"Mohamed-Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Haro-del Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Hern\u00e1ndez-Terciado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Eiros-Bachiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Villacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo A.","family":"Pascual-Figal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2024.10.010_bib1","first-page":"512","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.10.010_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"Abouezzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.10.010_bib5","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Pav\u00eda P, Garc\u00eda-Pinilla JM, Lozano-Bahamonde A, et\u00a0al. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study [e-pub ahead of print]. Rev Espa\u00f1ola Cardiol (English Edition) doi:10.1016\/j.rec.2024.07.005.","DOI":"10.1016\/j.rec.2024.07.005"},{"key":"10.1016\/j.cjca.2024.10.010_bib6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2024.10.010_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1073503","article-title":"Changing paradigm in the treatment of amyloidosis: from disease-modifying drugs to anti-fibril therapy","volume":"9","author":"Quarta","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjca.2024.10.010_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.10.010_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cjca.2024.10.010_bib10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.10.010_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib13","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.10.010_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2024.10.010_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cjca.2024.10.010_bib16","first-page":"61128","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","author":"Donnellan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.10.010_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cjca.2024.10.010_bib18","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2024.10.010_bib19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/0002-9343(47)90055-7","article-title":"Electrocardiographic patterns of ventricular hypertrophy as obtained by unipolar precordial and limb leads","volume":"2","author":"Sokolow","year":"1947","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2024.10.010_bib20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib21","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis: a systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2024.10.010_bib22","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.10.010_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2024.10.010_bib24","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/CIRCULATIONAHA.122.060596","article-title":"Targeted screening for transthyretin amyloid cardiomyopathy in patients with atrial fibrillation","volume":"146","author":"Prasad","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.10.010_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.10.010_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib27","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.10.010_bib28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2024.10.010_bib29","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.10.010_bib30","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jcmg.2023.05.002","article-title":"Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis: T-Amylo","volume":"16","author":"Arana-Achaga","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.10.010_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2024.10.010_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2024.10.010_bib33","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.10.010_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2024.10.010_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.rec.2022.08.001","article-title":"Cardiac amyloidosis and left atrial appendage closure: the CAMYLAAC study","volume":"76","author":"Amat-Santos","year":"2023","journal-title":"Rev Espa\u00f1ola Cardiol (English Edition)"},{"key":"10.1016\/j.cjca.2024.10.010_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.recesp.2022.10.019","article-title":"New challenges in the management of patients with transthyretin cardiac amyloidosis: beyond oral anticoagulation","volume":"76","author":"de Frutos","year":"2023","journal-title":"Rev Esp Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24010286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24010286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:10:24Z","timestamp":1739229024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X24010286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0828282X24010286"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2024.10.010","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2024.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}